News

NEWS


                    Investment to expand Chemotargets portfolio of leading drug discovery solutions The transaction adds to a growing number of holdings of the Prous group in academic spin-off companies Barcelona, May 2017 – Prous Institute for Biomedical Research announced today that it has made a strategic investment in C...


A paper authored by Dr Josep Prous, Vice President of Prous Institute for Biomedical Research, published in Japan’s CBI Journal describes the advances in information technologies which allow complex data scenarios to be analyzed, and highlights the development of predictive models which correlate the features of small molecule with properties of pharmacological interest, including therapeuti...


Prous Institute has been invited to speak at the Chem-Bio Informatics Society (CBI) Annual Meeting   "Future outlook of in silico drug discovery: Collaboration of simulation, structural biology and big data for innovative drug discovery" which takes place in Tokyo, Oct. 24-27, 2016.    During the Focused Session "Computational toxicology related topics" (Weds Oct. 26, 1...


27 August, 2016. Manchester, UK. Prous Institute for Biomedical Research is to present the 2016 Prous Institute – Overton &Meyer Award to Professor Jan Steyaert, at the XXIV International Symposium onMedicinal Chemistry organized by the European Federation of Medicinal Chemistry (EFMC). The award, conferred every two years, recognizes outstanding contributions to the development o...


12 May 2016. Prous Institute will be exhibiting at the 17th Drug Discovery Summit and 4th Discovery Chemistry & Drug Design Congress, 13-14 June 2016. At the exhibition, the latest version of our predictive analytics platform, Symmetry, and Global Mechanism of Action (GMoA) pharmacological profiling tool will be presented. In a single predictive model, Symmetry GMoA screens over 1,000 m...


Barcelona, Spain:  Prous Institute for Biomedical Research (PIBR) has announced today a research collaboration with the Broad Institute of MIT and Harvard implementing novel computational target action prediction methods to develop mechanistic hypotheses for small molecules. As part of the research plan Prous Institute will use their proprietary computational methods to predict targets fo...


Prous Institute has been invited to speak at the 136th Annual Meeting of the Pharmaceutical Society ofJapan (March 26-29, 2016) to be held at the Pacifico Yokohama Conference Center. The Pharmaceutical Society of Japan promotes the development of pharmaceutical sciences among its more than 20,000 members, which include chemists, physicists, biologists, and a wide profile of life science speci...


Prous Institute will be exhibiting at the Society of Toxicology’s 55th Annual Meeting and Tox Expo,  13-17 March 2016, with booth number 1637. At the exhibition, the latest version of our predictive analytics platform Symmetry’s Global Mechanism of Action (GMoA) will be presented. In a single predictive model, Symmetry GMoA (v11.2) screens over 1,000 mechanisms of action (...


Prous Institute has been invited to speak at the Chem-Bio Informatics Society (CBI) Annual Meeting "Open Innovation in drug discovery: emerging fields accelerated by in silico technologies " which takes place in Tokyo, Oct. 27-29, 2015.   During the CBI session "Computational Toxicology Focused" Oct. 27 (Tue) 16:00-17:30, Josep Prous, Jr., Ph.D., Vice President Research and Developme...


Barcelona. Prous Institute for Biomedical Research is proud to announce the nomination call for the 2016 Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery. Following their tradition of drug discovery science and technology, Prous Institute has donated the award biennially since 2004, acknowledging outstanding achievements in the field of medicinal chemistry....

Category: News, Technology

Barcelona. Prous Institute announced today the deployment of its predictive analytics platform, Symmetry, at the California Institute for Biomedical Research (Calibr). Under the terms of the agreement, Calibr will employ the new resource in its translational research activities, leveraging Symmetry’s Global Mechanism of Action (GMoA) model for hypothesis generation in drug design and to...


The Neurodegenerative Diseases group will assess a group of pharmacological compounds that induce autophagy in the lab and in animal models. Barcelona.  The Neurodegenerative Diseases Group of Vall d’Hebron Institute of Research (VHIR) has signed an agreement with Prous Institute for Biomedical Research to assess in in vivo and in vitro models of Parkinson’s disease a group o...


Prous Institute has been invited to speak at the Chem-Bio InformaticsSociety (CBI) Meeting on Drug Repositioning taking place at the Sanjo Kaikan Auditorium, Tokyo University on May 28, 2015. Drug repositioning has emerged in recent years as common practice to nurture pharmaceutical companies’ pipelines. Exploring a known drug for further indications with a reasonable degree of conf...


30 April 2015.  Ryoka Systems, distributor for Prous Institute for Biomedical Research in Japan, has been invited to speak at the BIOtech 2015, part of Asia’s largest Bio event, Life Science World. On May 14, 2015 (Thu) 12:20-13:20, Atsushi Kanou, General Manager, Computational Science Dept., will present “Prous Institute Symmetry: Computational approach in drug discovery”, ...


Barcelona, Spain: The Prous Institute for Biomedical Research (PIBR) today announced a collaboration with the National Institute of Health’s National Center for Advancing Translational Sciences (NCATS) to help advance assessing environmental chemical and drug safety. The research goal is to develop and validate quantitative structure – activity relationship (QSAR) models as tools to pr...


Prous Institute Symmetry has been used by the U.S. Department of Health and Human Services’ National Toxicology Program (NTP) as part of a battery of in silico analyses of the potential toxicity of chemicals spilt in January 2014 in the Elk River, West Virginia, U.S.A.   A chemical mixture used for cleaning coal was accidently released into the river, resulting in contaminati...


Symmetry's Global Mechanism of Action (GMoA) model provides decision support in the multi-target approach to deliberately combine in a single molecule scaffolds related to different therapeutic targets. This case study is performed with molecules reported in a recent paper describing the first compound exhibiting gamma-Secretase modulation, PPARgamma agonism and 5-LOX inhibition for the potential ...


Prous Insitute is pleased to announce the launch of our new website showcasing the features and benefits of Symmetry, the world’s first integrated predictive platform for drug discovery and safety evaluation.  To visit the website please click here.   


Prous Institute has been invited to speak at the R&D Head Club Meeting taking place in Tokyo, Feb. 6, 2015 at the Kitasato University School of Pharmacy Convention Hall. The meeting, organized by Professor Masahiro Takeuchi from Kitasato University’s, School of Pharmaceutical Sciences, will bring together an audience of clinical research mangers from leading Japanese and multinational ph...


Symmetry's Global Mechanism of Action (GMoA) model helps anticipate potential off-target safety liabilities of new structures early in drug discovery. This case study is performed with molecules reported in a recent paper describing the optimization of compounds for the potential treatment of Alzheimer ’s disease, minimizing cardiovascular liabilities (hERG channel blockade). To recei...


Prous Institute has been invited to speak at the Chem-Bio Informatics Society (CBI) Annual Meeting "iPS cells, Ion channels, in silico Technologies: Leading to a New Drug Discovery Paradigm" which takes place in Tokyo, Oct. 28-30, 2014. During the CBI session "in silico approaches for drug targets" Oct. 29 (Wed) 14:00-15:30, Josep Prous, Jr., Ph.D., Vice President Research and Development, will p...


Sept 7, 2014. Lisbon, Portugal. Prous Institute for Biomedical Research is to present the 2014 Prous Institute – Overton & Meyer Award to Dr György Keserű and Dr György Ferenczy from the Research Center for Natural Sciences of the Hungarian Academy of Sciences, at the 23rd International Symposium on Medicinal Chemistry organized by the European Federation of Medicinal Chemistry...


Prous Institute for Biomedical Research, a sponsor of Informa's 7th Annual Genotoxic Impurities Conference to be held in Berlin, June 24-25, 2014, will present the SYMMETRY, the world’s first integrated in silico solution for drug discovery and safety screening. The platform features models for a wide range of efficacy and toxicology endpoints, including bacterial mutagenicity to support the...


At the 16th International Workshop on Quantitative Structure-Activity Relationships in Environmental and Health Sciences in Milan (QSAR 2014) Prous Institute will present a poster on SYMMETRY's Global Mechanism of Action (MoA) model and an interesting application of the model to predict the relevant mechanisms of action associated with a binary data set for a given endpoint. A case study is descri...


Prous Institute for Biomedical Research, a sponsor of the GTA ANNUAL MEETING to be held in Newark, Delaware, May 7-8, 2014, will introduce SYMMETRY, the world’s first integrated in silico solution for drug discovery and safety screening.  The platform integrates models for a wide range of efficacy, toxicology and human adverse events endpoints. Prous Institute will present a poster on t...


Prous Institute for Biomedical Research will participate in the 53rd ANNUAL SOT MEETING to be held in Phoenix, Mar 24-27, 2014.  Prous Institute Symmetry®, the world’s first integrated in silico solution for drug discovery and safety screening, supports decisions in the design and optimization of drug candidates and helps minimize potential liabilities in the earliest stages of drug...


Prous Institute for Biomedical Research, a sponsor of the ANNUAL PREDICTIVE TOXICOLOGY SUMMIT to be held in London, Feb. 25-26, 2014, will introduce Prous Institute Symmetry®, the world’s first integrated in silico solution for drug discovery and safety screening.  The platform integrates models for a wide range of efficacy, toxicology and human adverse events endpoints, including m...


A new paper co-authored by scientists at US FDA and Prous Institute for Biomedical Research describes the development and validation of a QSAR model to predict Salmonella t. mutagenicity (Ames assay outcome) of pharmaceutical impurities using Prous Institute SYMMETRY SM, the world’s first integrated in silico solution for drug discovery and safety screening.  Data was sourced from publi...


Prous Institute will participate in the Annual Genotoxic Impurities Conference to be held in Berlin, June 19-20th to present its new in silico predictive platform, SYMMETRY®.  Attendees will have the opportunity to learn about SYMMETRY®’s QSAR models for predicting the mutagenic potential of drug impurities in accordance with ICH M7, developed in collaboration with the U.S. FDA....


Prous Institute for Biomedical Research is pleased to announce the publication of its new WIPO patent application: Pyrano[3,2-c][2]benzopyran-6(2H)-one derivatives and uses thereof.  Claimed  compounds have shown inhibitory activity against SGLT2 (type 2 sodium-glucose linked transporter) and have displayed positive effects in glycemia control in animal models. SGLT2 inhibitors promote t...


A new paper published by US FDA scientists (In silico modeling to predict drug-induced phospholipidosis; Sydney S. Choi, Jae S. Kim, Luis G. Valerio Jr., Nakissa Sadrieh;  Toxicol Appl Pharmacol. 269 (2013) 195–204) explores the use of Prous Institute’s SYMMETRY® in the construction and validation of QSAR models for the identification of drug-induced phospholipidosis (DIPL). T...


Barcelona: Prous Institute for Biomedical Research was the prize winner in the category “Innovation at the Core: Contribution to Sector Growth” at the first Trade & Innovation Awards held by the American Chamber of Commerce in Spain, AmChamSpain.  The awards seek to promote transatlantic relations and drive the internationalization of business as an engine for economic recover...

Category: News

Berlin, Germany: Prous Institute for Biomedical Research has announced the presentation of study results using its proprietary computational platform, Symmetry®, to identify molecular and cellular targets involved in neuroplasticity and tumor cell proliferation at the 22nd International Symposium on Medicinal Chemistry organized by the European Federation of Medicinal Chemistry (EFMC). Prous...


Berlin, Germany: Prous Institute for Biomedical Research presented the 2012 Prous Institute – Overton & Meyer Award, recognizing outstanding contributions to the development of new technologies in the field of medicinal chemistry, to Dr Harren Jhoti, at the 22nd International Symposium on Medicinal Chemistry organized by European Federation of Medicinal Chemistry (EFMC). This award ack...


Vienna, Austria: Prous Institute for Biomedical Research and the FDA Center for Drug Evaluation and Research (CDER) will present the results of their work to develop reliable mutagenicity models with a new release of Prous Institute’s Symmetry® computational platform and FDA/NCTR Mold2 descriptor package.  Prous Institute and the FDA/CDER are jointly presenting the research findings...


Natural products are attractive sources for discovering new drugs. The undisclosed mechanisms of action of thousands of molecular entities from medicinal plants remain to be elucidated, and experimental screening of these compounds is time-consuming and costly.  Structure-based data mining technologies and computational models (SYMMETRY®) developed at Prous Institute allow rapid and relia...


Innovative in silico approach opens new avenues in drug discovery for the treatment of CNS disorders   Barcelona: Prous Institute for Biomedical Research is presenting the results of its work to construct a predictive computational system mimicking the different processes involved in neuroplasticity with the aim of identifying molecules with potential pharmacological activity.   ...


Boston, MA, USA: Prous Institute will be participating in the Business Partnering Forum at the BIO International Convention and welcomes the opportunity to discuss potential partnerships with companies interested in our preclinical candidates and/or the application of our SYMMETRY® technology to new areas of research.  Our proprietary drug discovery platform, SYMMETRY®, enables the di...

Category: News, Symmetry

San Francisco, March 15, 2012 - Prous Institute for Biomedical Research and the FDA Center for Drug Evaluation and Research (CDER)  have found promising validation results for the predictive performance of mutagenicity models using Prous Institute's Symmetry® computational software and the FDA/NCTR Mold2 descriptor package. Prous Institute and the FDA/CDER are jointly presenting the...


San Francisco, March 14, 2012 - Prous Institute for Biomedical Research has reported encouraging statistically significant results for cross-validation and external validation of cytochrome P450 3A4 and 2D6 inhibitor models created using its BioEpisteme® predictive software. The findings are a result of an FDA-approved research collaboration and are being presented jointly with the FDA Center ...


Compounds developed using Prous Institute Symmetry® Drug Discovery Platform open new avenues in cancer treatment Prous Institute for Biomedical Research has announced the recent publishing of its new WIPO patent application. The cited compounds figured among the new magnolol and honokiol derivatives obtained at the Prous Institute for Biomedical Research that have shown inhibitory activ...


Barcelona, January 12, 2012 – Prous Institute for Biomedical Research is proud to announce the nomination call for the 2012 Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery. Following their tradition of drug discovery science and technology, Prous Institute has donated the award biennially since 2004, acknowledging outstanding achievements in the field of m...

Category: News, Technology

Washington D.C., USA: The Food and Drug Administration's Center for Food Safety and Applied Nutrition(FDA/CFSAN) and Prous Institute for Biomedical Research (PIBR) will work jointly under a 5 year research collaboration agreement (RCA) to develop hypothesis based in silico predictive tools that are consistent with CFSAN's and FDA’s Critical Path Initiative.This research will benefit CFSAN, t...


Washington D.C., USA: Prous Institute for Biomedical Research will be jointly presenting a scientific poster with the US FDA Center for Drug Evaluation and Research (CDER) at the Annual Meeting of the Society of Toxicology in Washington D.C.. The poster is titled: “Computational Modeling for QT Prolongation: A Drug Cardiovascular Safety Endpoint of Paramount Importance”. The poster wil...


Washington D.C., USA: Prous Institute’s BioEpisteme® software will be featured in a scientific poster to be presented by the US FDA Center for Drug Evaluation and Research (CDER), Office of Pharmaceutical Science (OPS), at the Annual Meeting of the Society of Toxicology in Washington D.C., March 6th-10th 2011. The poster is titled: “In silico Predictive Model for Drug-Induced Phosp...